newsfilter
← Latest News
Business Wire·

Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio

Long COVID Trial Topline data expected in early Q3 2022 NASH Trial interim data expected in late Q3 2022 OHE Trial Suspended Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat com